3 Health Care Stocks Pushing The Sector Higher

All three major indices traded up today with the Dow Jones Industrial Average ( ^DJI) trading up 56 points (0.3%) at 17,533 as of Monday, Aug. 17, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,658 issues advancing vs. 1,301 declining with 196 unchanged.

The Health Care sector as a whole closed the day up 1.7% versus the S&P 500, which was up 0.3%. Top gainers within the Health Care sector included Escalon Medical ( ESMC), up 3.7%, XTL Biopharmaceuticals ( XTLB), up 3.4%, Reliv' International ( RELV), up 12.1%, USMD Holdings ( USMD), up 2.1% and VBI Vaccines ( VBIV), up 3.6%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the sector higher today:

VBI Vaccines ( VBIV) is one of the companies that pushed the Health Care sector higher today. VBI Vaccines was up $0.09 (3.6%) to $2.60 on light volume. Throughout the day, 3,813 shares of VBI Vaccines exchanged hands as compared to its average daily volume of 5,100 shares. The stock ranged in a price between $2.54-$2.68 after having opened the day at $2.54 as compared to the previous trading day's close of $2.51.

VBI Vaccines has a market cap of $49.9 million and is part of the drugs industry. Shares are down 24.6% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close, Reliv' International ( RELV) was up $0.11 (12.1%) to $1.02 on heavy volume. Throughout the day, 53,313 shares of Reliv' International exchanged hands as compared to its average daily volume of 9,300 shares. The stock ranged in a price between $0.93-$1.10 after having opened the day at $1.02 as compared to the previous trading day's close of $0.91.

Reliv' International, Inc. develops, manufactures, and markets nutritional supplements that promote basic nutrition, wellness needs, weight management, and sports nutrition. Reliv' International has a market cap of $14.4 million and is part of the drugs industry. Shares are down 22.2% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate Reliv' International a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Reliv' International as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and reasonable valuation levels. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

Highlights from TheStreet Ratings analysis on RELV go as follows:

  • RELV's revenue growth has slightly outpaced the industry average of 2.1%. Since the same quarter one year prior, revenues slightly increased by 2.5%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • RELV's debt-to-equity ratio is very low at 0.24 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.90 is somewhat weak and could be cause for future problems.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. When compared to other companies in the Personal Products industry and the overall market, RELIV INTERNATIONAL INC's return on equity is below that of both the industry average and the S&P 500.
  • RELV has underperformed the S&P 500 Index, declining 14.51% from its price level of one year ago. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.

You can view the full analysis from the report here: Reliv' International Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

XTL Biopharmaceuticals ( XTLB) was another company that pushed the Health Care sector higher today. XTL Biopharmaceuticals was up $0.06 (3.4%) to $1.85 on light volume. Throughout the day, 350 shares of XTL Biopharmaceuticals exchanged hands as compared to its average daily volume of 3,800 shares. The stock ranged in a price between $1.68-$1.85 after having opened the day at $1.68 as compared to the previous trading day's close of $1.79.

XTL Biopharmaceuticals has a market cap of $24.6 million and is part of the drugs industry. Shares are down 9.6% year-to-date as of the close of trading on Friday.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.